<DOC>
	<DOCNO>NCT03018028</DOCNO>
	<brief_summary>This trial conduct Asia . The aim trial investigate dose-response relationship once-daily dose three dose level ( 3 , 7 14 mg ) oral semaglutide versus placebo monotherapy glycaemic control Japanese subject type 2 diabetes mellitus</brief_summary>
	<brief_title>Dose-response , Safety Efficacy Oral Semaglutide Versus Placebo Versus Liraglutide , All Monotherapy Japanese Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Informed consent obtain trialrelated activity . Trialrelated activity procedure carry part trial , include activity determine suitability trial Japanese male female , age equal 20 year time signing informed consent Diagnosed type 2 diabetes mellitus least 30 day prior day screen HbA1c 6.5 % −9.5 % ( 48−80 mmol/mol ) ( inclusive ) subject treat oral antidiabetic drug monotherapy 7.0 % −10.0 % ( 53−86 mmol/mol ) ( inclusive ) subject treat diet exercise therapy alone Treatment least 30 day prior day screen ; stable daily dose oral antidiabetic drug monotherapy ( allow oral antidiabetic drug : metformin , sulphonylurea , glinide , αglucosidase inhibitor , dipeptidyl peptidase4 inhibitor sodiumglucose cotransporter2 inhibitor ) halfmaximum approve dose accord Japanese labelling addition diet exercise therapy . diet exercise therapy alone Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method . Adequate contraceptive measure abstinence ( sex ) , diaphragm , condom ( partner ) , intrauterine device , sponge , spermicide oral contraceptive Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol Family personal history multiple endocrine neoplasia type 2 ( MEN 2 ) medullary thyroid carcinoma ( MTC ) History pancreatitis ( acute chronic ) History major surgical procedure involve stomach potentially affect absorption trial product ( e.g . subtotal total gastrectomy , sleeve gastrectomy , gastric bypass surgery ) Any follow : myocardial infarction , stroke hospitalisation unstable angina transient ischaemic attack within past 180 day prior day screen randomisation Subject presently classify New York Heart Association ( NYHA ) Class IV Planned coronary , carotid peripheral artery revascularisation know day screen Subjects alanine aminotransferase ( ALT ) 2.5 x upper normal limit ( UNL ) Renal impairment define estimate Glomerular Filtration Rate ( eGFR ) 30 mL/min/1.73 m^2 per Chronic Kidney Disease Epidemiology Collaboration formula ( CKDEPI ) Treatment onceweekly glucagonlike peptide1 receptor agonist ( GLP1 RA ) , weekly dipeptidyl peptidase4 ( DPP4 ) inhibitor thiazolidinedione period 90 day day screen Treatment medication indication diabetes obesity state inclusion criterion period 60 day day screen . An exception shortterm insulin treatment acute illness total equal 14 day Proliferative retinopathy maculopathy require acute treatment . Verified fundus photography dilate fundoscopy perform within 90 day prior randomisation History presence malignant neoplasm within last 5 year ( except basal squamous cell skin cancer insitu carcinoma ) Initiation antidiabetic medication day screen day randomisation</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>